Cost Effectiveness Analysis of Exemestane Versus Capecitabine Monotherapy for Patients with Hormone Receptor–Positive and Her2-Negative, Metastatic Breast Cancer from National Cancer Institute Prespective in Egypt
Abstract
Authors
H Abdallah AS Abourawash M Elgazzar A Helal